Protection against meningococcal serogroup ACYW disease in complement-deficient individuals vaccinated with the tetravalent meningococcal capsular polysaccharide vaccine. 1998

C A Fijen, and E J Kuijper, and M Drogari-Apiranthitou, and Y Van Leeuwen, and M R Daha, and J Dankert
Department of Medical Microbiology, Reference Laboratory for Bacterial Meningitis, University of Amsterdam and National Institute for Public Health and Environmental Protection, Amsterdam, The Netherlands.

Individuals with properdin, C3 or late complement component deficiency (LCCD) frequently develop meningococcal disease. Vaccination of these persons has been recommended, although reports on efficacy are scarce and not conclusive. We immunized 53 complement-deficient persons, of whom 19 had properdin deficiency, seven a C3 deficiency syndrome and 27 had LCCD with the tetravalent (ACYW) meningococcal capsular polysaccharide vaccine. Serological studies were performed in 43 of them. As controls 25 non-complement-deficient relatives of the complement-deficient vaccinees and 21 healthy non-related controls were vaccinated. Post-vaccination, complement-deficient individuals and controls developed a significant immunoglobulin-specific antibody response to capsular polysaccharides group A, C, Y, W135, but a great individual variation was noticed. Also, the proportion of vaccinees of the various vaccinated groups with a significant increase in bactericidal titre (assayed with heterologous complement) was similar. Opsonization of meningococci A and W135 with sera of the 20 LCCD individuals yielded in 11 (55%) and eight (40%) sera a significant increase of phagocytic activity after vaccination, respectively. Despite vaccination, four complement-deficient patients experienced six episodes of meningococcal disease in the 6 years post-vaccination. Four episodes were due to serogroup B, not included in the vaccine. Despite good response to serogroup Y upon vaccination, disease due to serogroup Y occurred in two C8beta-deficient patients, 3.5 and 5 years post-vaccination. These results support the recommendation to vaccinate complement-deficient individuals and to revaccinate them every 3 years.

UI MeSH Term Description Entries
D008297 Male Males
D008589 Meningococcal Infections Infections with bacteria of the species NEISSERIA MENINGITIDIS. Meningococcal Septicemia,Infections, Meningococcal,Meningococcal Disease,Infection, Meningococcal,Meningococcal Diseases,Meningococcal Infection,Septicemia, Meningococcal
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009345 Neisseria meningitidis A species of gram-negative, aerobic BACTERIA. It is a commensal and pathogen only of humans, and can be carried asymptomatically in the NASOPHARYNX. When found in cerebrospinal fluid it is the causative agent of cerebrospinal meningitis (MENINGITIS, MENINGOCOCCAL). It is also found in venereal discharges and blood. There are at least 13 serogroups based on antigenic differences in the capsular polysaccharides; the ones causing most meningitis infections being A, B, C, Y, and W-135. Each serogroup can be further classified by serotype, serosubtype, and immunotype. Diplokokkus intracellularis meningitidis,Meningococcus,Micrococcus intracellularis,Micrococcus meningitidis,Micrococcus meningitidis cerebrospinalis,Neisseria weichselbaumii
D010587 Phagocytosis The engulfing and degradation of microorganisms; other cells that are dead, dying, or pathogenic; and foreign particles by phagocytic cells (PHAGOCYTES). Phagocytoses
D011414 Properdin A 53-kDa protein that is a positive regulator of the alternate pathway of complement activation (COMPLEMENT ACTIVATION PATHWAY, ALTERNATIVE). It stabilizes the ALTERNATIVE PATHWAY C3 CONVERTASE (C3bBb) and protects it from rapid inactivation, thus facilitating the cascade of COMPLEMENT ACTIVATION and the formation of MEMBRANE ATTACK COMPLEX. Individuals with mutation in the PFC gene exhibit properdin deficiency and have a high susceptibility to infections. Complement Factor P,Factor P, Complement
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children
D003176 Complement C3 A glycoprotein that is central in both the classical and the alternative pathway of COMPLEMENT ACTIVATION. C3 can be cleaved into COMPLEMENT C3A and COMPLEMENT C3B, spontaneously at low level or by C3 CONVERTASE at high level. The smaller fragment C3a is an ANAPHYLATOXIN and mediator of local inflammatory process. The larger fragment C3b binds with C3 convertase to form C5 convertase. C3 Complement,C3 Precursor,Complement 3,Complement C3 Precursor,Complement Component 3,Precursor-Complement 3,Pro-C3,Pro-Complement 3,C3 Precursor, Complement,C3, Complement,Complement, C3,Component 3, Complement,Precursor Complement 3,Precursor, C3,Precursor, Complement C3,Pro C3,Pro Complement 3
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

C A Fijen, and E J Kuijper, and M Drogari-Apiranthitou, and Y Van Leeuwen, and M R Daha, and J Dankert
April 1995, Clinical and experimental immunology,
C A Fijen, and E J Kuijper, and M Drogari-Apiranthitou, and Y Van Leeuwen, and M R Daha, and J Dankert
July 2009, Journal of the Formosan Medical Association = Taiwan yi zhi,
C A Fijen, and E J Kuijper, and M Drogari-Apiranthitou, and Y Van Leeuwen, and M R Daha, and J Dankert
October 2003, Vaccine,
C A Fijen, and E J Kuijper, and M Drogari-Apiranthitou, and Y Van Leeuwen, and M R Daha, and J Dankert
July 1993, The Journal of infectious diseases,
C A Fijen, and E J Kuijper, and M Drogari-Apiranthitou, and Y Van Leeuwen, and M R Daha, and J Dankert
August 2008, Therapeutics and clinical risk management,
C A Fijen, and E J Kuijper, and M Drogari-Apiranthitou, and Y Van Leeuwen, and M R Daha, and J Dankert
December 2021, Vaccine,
C A Fijen, and E J Kuijper, and M Drogari-Apiranthitou, and Y Van Leeuwen, and M R Daha, and J Dankert
January 2003, Vaccine,
C A Fijen, and E J Kuijper, and M Drogari-Apiranthitou, and Y Van Leeuwen, and M R Daha, and J Dankert
May 2006, Infection and immunity,
C A Fijen, and E J Kuijper, and M Drogari-Apiranthitou, and Y Van Leeuwen, and M R Daha, and J Dankert
January 2000, Journal of clinical immunology,
C A Fijen, and E J Kuijper, and M Drogari-Apiranthitou, and Y Van Leeuwen, and M R Daha, and J Dankert
September 2020, Journal of the Pediatric Infectious Diseases Society,
Copied contents to your clipboard!